A phase 3 clinical trial found that the ustekinumab biosimilar CT-P43 demonstrated equivalent efficacy, safety, and ...
Scoping review shows clinicians and patients still worry about biosimilar insulin switching, devices and safety—evidence gaps ...
Real-world evidence shows switching between etanercept products and etanercept biosimilars preserves efficacy and safety, ...
One-year trial shows AVT05 golimumab biosimilar matches Simponi in rheumatoid arthritis, including switching, with comparable ...
Celltrion leads biosimilars in Asia, biosimilars in Europe expand, while Sandoz restructures and FDA hurdles loom.
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine ...
While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results